Zero-Magnetic Medicine at an Inflection Point: Pioneering Functional Diagnostics with Ultra-Weak Biomagnetic Signals

When an emergency department physician encounters a patient with chest pain of unknown etiology, or when a neurologist needs to evaluate an autistic child who is unable to remain still, clinicians face a common underlying need: Is there a technology that canNon-invasive, rapid, and intuitive “visualization” of functional activities in human organs, rather than merely observing its static anatomical structures?

Zero-Field Medicine (fully named “Ultra-Weak Magnetic Functional Information Medicine”) is an emerging frontier technology developed to meet this need. By creating a near-zero magnetic field measurement environment and employing highly sensitive quantum sensors such as atomic magnetometers, it captures ultra-weak biomagnetic signals spontaneously generated by organs like the heart and brain, with intensities ranging from one hundred-millionth to one-billionth of the Earth’s magnetic field, thereby enabling the detection of early “functional changes” associated with disease onset.

In the past, this technology remained largely confined to laboratories; today, however, it has reached a true turning point in industrialization. CardioFlux, a room-temperature magnetocardiography (MCG) system from the United States, became the first to receive FDA approval, while China’s first domestically produced magnetoencephalography (MEG) imaging system successfully obtained regulatory clearance. Meanwhile, teams both in China and abroad—including Cerca, FieldLine, and Hangzhou Zero-Mag Medical—are concurrently advancing the clinical deployment of wearable MEG, room-temperature MCG, and lightweight magnetic shielding devices.

Starting from this inflection point, this article will delve into the core forces driving the industrialization of zero-magnetic medicine, map out the strategic layouts and technological roadmaps of representative global enterprises, explore how this frontier technology takes the critical leap from the laboratory to clinical practice, and chart its course toward a broader future industrial landscape.

Zero-Field Medicine did not emerge out of thin air; rather, it represents a concentrated breakthrough at a critical juncture following the long-term evolution of medicine, electromagnetism, and engineering technology. To understand its validity, one must first revisit the history of human observation of bioelectrical activity.

For a long time, clinical understanding of bioelectrical activity has primarily relied on electrode-based contact technologies, such as electrocardiography (ECG) and electroencephalography (EEG). While these techniques are mature and convenient, their physical nature imposes fundamental limitations: electrical signals undergo varying degrees of attenuation and distortion as they propagate through tissues, resulting in low spatial resolution and imprecise localization of deep current sources.

To circumvent the physical constraints of “contact measurement,” scientists began shifting toward magnetic signal pathways in the latter half of the 20th century. Unlike electrical signals, the magnetic fields generated by bioelectric currents within the body are hardly affected by tissue conductivity, thereby more accurately reflecting the location and propagation direction of the current sources. This insight spurred early research into magnetocardiography (MCG) and magnetoencephalography (MEG).

However, for decades, magnetometry technology has been constrained by two formidable barriers:Ultra-Weak Signals and Extremely Demanding Sensors. The intensity of human biomagnetic signals is extremely low; magnetocardiographic (MCG) signals are approximately one-millionth of the Earth’s magnetic field, while magnetoencephalographic (MEG) signals are as low as one-billionth. Meanwhile, the only viable high-sensitivity sensor available in the early stages—the Superconducting Quantum Interference Device (SQUID)—required operation in a near-absolute-zero environment dependent on liquid helium, resulting in bulky, expensive, and complex systems that confined the technology strictly to top-tier laboratories.

True transformation stems from the concurrent maturation of multiple enabling technologies over the past decade at the intersection of “cost reduction, lightweight design, and clinical friendliness.” The core of zero-field medicine is not the pursuit of an absolute “zero magnetic field,” but rather the reconstruction of how life’s magnetic signals are captured and interpreted through a three-tiered, progressive systems engineering approach.

The first layer is“Environmental Shielding”. Any unprocessed geomagnetic fields, equipment magnetic noise, or urban electromagnetic interference may obscure the body’s magnetic field signals. Therefore, establishing a “near-zero magnetic” silent environment through technologies such as high-performance magnetic shielding chambers and active magnetic compensation is an indispensable prerequisite for capturing authentic signals.

The second layer is"Signal Sensing". In magnetically shielded environments, sensors are key. The reliance of SQUIDs on liquid helium has been overcome, and the maturation of optically pumped magnetometers (OPMs) represents a decisive breakthrough. These miniature quantum sensors, which operate at room temperature, have achieved sensitivity comparable to that of SQUIDs and further support array configuration and wearable integration. The new generation of atomic magnetometers, represented by SERF (spin-exchange relaxation-free) technology, has pushed sensitivity to new heights, collectively addressing the fundamental challenges of clinical deployment feasibility.

The third layer is"Magnetic Field Reconstruction and Modulation". After acquiring high-quality magnetic field signals, algorithms such as electromagnetic source localization are employed to reconstruct them into dynamic maps of cardiac electrical propagation or cerebral neural activity, achieving a perfect combination of “millisecond-level temporal resolution and millimeter-level spatial resolution.” More forward-looking is research into magnetic modulation, which utilizes specific ultra-weak time-varying magnetic fields to non-invasively intervene in neuronal activity, thereby opening up entirely new physical therapy pathways for conditions such as epilepsy and depression.

It is evident that zero-magnetism medicine constitutes a multidisciplinary field of engineering medicine, spanning materials science, quantum sensing, algorithmic modeling, and clinical engineering. It is this “shielding–sensing–decoding” framework that endows it with the fundamental capability to transform clinical paradigms: for the first time, human electromagnetic physiological activities can be directly “visualized” in a completely non-invasive manner with high spatiotemporal resolution. This has brought about two paradigm shifts:

● Front-loaded Diagnosis: To capture early functional signals of abnormal electrical activity before structural lesions develop in organs. For example, to identify subtle current abnormalities caused by myocardial ischemia when coronary arteries are not yet significantly narrowed, thereby achieving true “early screening.”

● Functional Assessment: Provides dynamic information that traditional imaging cannot reveal. For example, it can precisely localize the discharge origin and propagation pathways of epileptic foci, or map the millisecond-level collaborative networks among different brain regions during cognitive tasks.

Therefore, the zero-magnetic environment is not an end in itself, but a prerequisite for achieving high-fidelity capture of biomagnetic signals. It functions as an extremely sensitive “magnetic microscope,” enabling us to observe the most fundamental electrophysiological activities of life, thereby advancing medical diagnosis and intervention into an era characterized by earlier, more precise, and more dynamic functional information.

In recent years, zero-magnetism medicine has reached a critical turning point, driven by the national strategy of “self-reliance and controllability in high-end medical equipment” and the urgent clinical need for precise diagnosis and treatment of cardiovascular, cerebrovascular, and brain science-related diseases. This field is no longer merely a subject of study for physicists and neuroscientists but is increasingly coming into the shared focus of clinicians, hospital administrators, and industrial capital.

On one hand, cardiovascular and cerebrovascular diseases have long ranked among the leading causes of death and disability in China and globally; however, existing imaging and electrophysiological tools still exhibit significant gaps in identifying ultra-early functional abnormalities. On the other hand, fields such as brain science research, precise epilepsy localization, and developmental disorder assessment continue to accumulate demand for high-temporal-resolution, non-invasive functional imaging, yet remain constrained by equipment complexity and high barriers to use. These unmet clinical needs are providing a genuine and urgent rationale for the practical implementation of zero-field medical technology.

As magnetocardiography (MCG) and magnetoencephalography (MEG) imaging equipment successively obtain regulatory approval, this technology is accelerating its transition from the laboratory into real-world clinical practice. This shift signifies not only the market authorization of individual products, but also marks a critical milestone where a class of frontier technologies, long confined to the research phase, begins to undergo rigorous validation within the healthcare system.

Globally, zero-field medical technology remains in a clearly defined early stage. The market has not yet achieved large-scale volume growth; its commercialization is driven more by regulatory approvals and the step-by-step validation of specific application scenarios. The number of installed units is not a core metric at this stage,What truly determines the direction of the industry is which clinical needs are validated first.

Unlike traditional large-scale imaging equipment such as MRI and CT, zero-field medical technology has not followed a linear expansion path of “maturation in research followed by large-scale deployment.” Instead, it has exhibited a more cautious development pace, characterized by high per-unit equipment costs and the need for stepwise validation of clinical value in real-world settings.

This nonlinear development pattern has given rise to differentiated validation and advancement strategies worldwide. In Europe and the United States, validation often begins in specialty clinics or through in-depth research collaborations. In China, by contrast, integration with the large-scale tertiary hospital system occurs at an earlier stage. Leveraging national industrial policies and targeted support, systematic clinical studies and engineering validation are conducted to accelerate the deployment of complete-device solutions into pilot applications.

Based on technological maturity and the stage of clinical validation, the industry has bifurcated into two main trajectories:

● Magnetocardiography (MCG) Imaging: Compared with traditional electrocardiography, magnetocardiography is more sensitive to early myocardial ischemia and microvascular disease, while also offering non-invasive and rapid assessment. It naturally fits the scenarios of emergency triage for chest pain and early screening. Its clinical value is relatively direct, and its commercial logic focuses on optimizing diagnostic and treatment workflows and reducing unnecessary invasive tests. Therefore, its commercialization path is clearer, and it has entered discussions on regulation and reimbursement systems at an earlier stage.

● Magnetoencephalography: Currently still in the stage of technological innovation and pilot implementation, applications are focused on specialized fields with urgent demands for brain functional information, such as epileptic focus localization, neurodevelopmental disorders, and psychiatric diseases. Despite its significant long-term potential, due to higher technical complexity and prolonged clinical validation cycles, it requires the accumulation of more robust clinical trial data and real-world evidence to demonstrate its added value; therefore, the commercialization pathway is expected to be longer.

As industrialization advances, a global industry chain with clear tiers and well-defined division of labor is rapidly taking shape:

Comparison Chart of Core Characteristics and Pathways in the Zero-Magnetic Medical Industry Chain

From upstream core sensors and weak magnetic environments, to the highly challenging midstream integration of complete system units, and finally to downstream clinical applications in hospitals, specialized ecosystem collaboration marks the entry of technological development into a new stage driven jointly by system efficiency and clinical value.

On this basis, as manufacturing costs decline and certification systems become more robust in the future, zero-field medical technology is poised to achieve deep integration with artificial intelligence, big data, and other technologies, evolving into smarter diagnostic and interventional platforms. For instance, CardioFlux has already employed AI algorithms for signal processing; emerging convergent directions such as multimodal imaging and “zero-field magnetoencephalography plus brain-computer interfaces” will further expand its application boundaries.

Against the backdrop of market-stage evolution and divergent development pathways, companies in the zero-field medical sector have, since 2018, begun to exhibit clear trends toward specialized division of labor and industrial clustering on a global scale.

Notably, this emerging sector has attracted significant capital attention, with the financing progress of representative companies both domestically and internationally revealing the market’s valuation logic and expectations for zero-field medical technology.

Currently, the representative enterprises in the global industrial chain of zero-magnetism medicine are as follows:

Overview of Zero-Field Magnetic Medicine Enterprises in China and Abroad

European and American companies tend to adopt a “lightweight, scenario-specific” technological approach, primarily leveraging optically pumped magnetometer (OPM) technology to develop wearable and highly adaptable magnetoencephalography (MEG) or magnetocardiography (MCG) detection systems. Their core objective is to lower the barrier to use, facilitating the transition of these examinations from specialized shielded rooms to dynamic environments such as outpatient clinics and homes.

In the field of magnetocardiography (MCG), the US company Genetesis stands out as a prime example. Its MCG system, CardioFlux, was the first to receive regulatory approval, strategically targeting the high-frequency scenario of emergency chest pain triage. Rather than aiming to replace existing diagnostic tests, it is designed to assist physicians in rapidly determining whether further invasive diagnostic or therapeutic interventions are necessary. This approach has enabled MCG to demonstrate its clinical value within real-world medical workflows.

In the field of magnetoencephalography (MEG), the UK-based company Cerca Magnetics represents a research-driven approach. Its wearable MEG system, based on optically pumped magnetometers (OPMs), emphasizes flexible deployment and wearability, aligning more closely with the needs of neuroscience research and specialized clinical applications. Meanwhile, FieldLine’s HEDscan system from the United States has further demonstrated the feasibility of operation in lightly shielded environments. Although this pathway entails a slower pace of commercialization, it enables the establishment of significant technical barriers and expert consensus within the specialty of neurology.

QuSpin holds a pivotal position at the core component level, with its OPM/SERF atomic magnetometer modules becoming essential underlying components for multiple overseas OEMs. This has significantly lowered the barrier to industry innovation and spurred diverse application explorations.

Overall, the industrialization momentum of global zero-field medicine currently exhibits regional divergence. Overseas enterprises’ innovation and capital allocation are more focused on deep optimization of traditional SQUID technology and consolidation of existing application scenarios, while remaining relatively cautious about the systematic expansion of next-generation technological pathways such as OPM. In contrast, China is advancing more rapidly in the integration of OPM and SERF technologies and the systems engineering of complete devices.

Comparison of Core Competitiveness Among Zero-Field Medical Enterprises in China and Abroad

For China, the exploration path of zero-magnetism medicine does not pursue short-term leadership in a single technological niche; rather, it is committed to building a comprehensive systems engineering framework that spans from source innovation to clinical implementation. This strategic choice stems from the deep integration of China’s unique industrial foundation, healthcare system, and national strategy.

Top-Level Design: Support from National Strategy and Systemic Resources

China’s development of zero-magnetism medicine has, from its inception, been situated within the grand narrative of national scientific and technological innovation and the self-reliance and controllability of high-end medical equipment.

At the policy level, it not only benefits from an expedited review pathway for innovative medical devices but has also been incorporated into the national major science and technology infrastructure plan under the 14th Five-Year Plan, securing robust support from special funds at both central and local levels. This top-level design has overcome the “valley of death” challenge commonly faced by emerging technologies in their early stages, positioning China as one of the few markets worldwide capable of simultaneously advancing basic research, engineering development, and clinical validation.

This support is specifically manifested in a unique collaborative model of “Major Science and Technology Infrastructure–Clinical Research–Industrial Translation.” For instance, the national “Ultra-High-Sensitivity Ultra-Weak Magnetic Field Major Science and Technology Infrastructure” under construction in Hangzhou provides a world-class platform for source-level technological innovation. Meanwhile, a dense network of industry-academia-research-medical collaboration ensures that laboratory breakthroughs can be rapidly validated and iterated in clinical settings.

Implementation Path: Whole-Machine Traction and Full-Chain Breakthrough

Under the national strategic framework, China has developed a well-tiered and collaboratively evolving corporate ecosystem that collectively supports the “system integration” approach.

Represented by Hangzhou Zero-Mag Medical, its complete magnetocardiography and magnetoencephalography imaging systems have both received regulatory approval, with equipment deployed for validation in multiple hospitals across China. The company has not only achieved a closed-loop technological integration from core components to complete systems but also spearheaded the establishment of the world’s first “Zero-Magnetic Interventional Medicine Laboratory,” expanding the technological frontier from diagnosis to ultra-early intervention, thereby fully demonstrating the leading capability of its “system-level engineering approach.”

A cohort of specialized whole-system manufacturers has achieved key breakthroughs in niche segments, establishing a diversified product portfolio. Kunmai Medical’s magnetoencephalography (MEG) system has received regulatory approval and is focused on high-end clinical applications of brain functional imaging, such as epileptic focus localization. Weici Technology has pioneered a new pathway with its liquid-helium-free MEG devices for cardiac and neurological applications, addressing the industry’s longstanding challenge of high operational and maintenance costs by completely eliminating dependence on liquid helium.

Exploration of frontier scenarios and R&D of new-form devices are simultaneously active. Zhongke Zhiying is dedicated to developing wearable magnetoencephalography (MEG) systems and mobile magnetic shielding enclosures, exploring the application of this technology in out-of-hospital and flexible settings. Ningbo CiBo Intelligence focuses on the R&D of wearable prototypes based on domestically produced sensors, building technical reserves for the future potential market of continuous home monitoring.

Upstream in the industrial chain, the process of achieving independent and controllable capabilities is advancing steadily. Guoqi Sensing has achieved mass production of ultra-high-sensitivity SERF atomic magnetometers, while companies such as Zero-Magnetic Equipment (Deqing) provide key engineered solutions like magnetic shielding chambers, jointly supporting the development of domestically produced complete systems.

Overall, leading overseas companies center on sensors, adopting scenario-specific and lightweight strategies to pursue agile penetration and value demonstration in niche markets. In contrast, China’s industry leverages system integration as its cornerstone, driving engineering implementation and continuous iteration of technologies across the entire ecosystem and diverse scenarios through a model led by complete devices and built on collaborative ecosystem development.

It is not difficult to see that the market for zero-magnetic medicine is still in its“Definition Phase” Rather Than “Expansion Phase”. The prominent features of this stage are:The global sample of core enterprises remains limited, with most companies’ financing still at an early stage and their technological and business model explorations far from being solidified., which precisely indicates that the entire industry holds vast room for definition and significant development potential.

Currently, China’s zero-magnetic medicine is standing at a critical inflection point for industrialization. With simultaneous advancements in technology, demand, and policy, its industrialization has entered a fast track. This is not merely a story of growth in the equipment market. The essence of zero-magnetic medicine lies in establishing a new monitoring system for function and information, beyond the well-known “structural imaging” and “biochemical indicators.”

However, a significant chasm remains to be bridged between “market approval” and “routine clinical adoption.” Industry challenges remain prominent:

First,Challenges in Clinical Validation and Standard SettingCurrently, research sample sizes are limited, and the lack of internationally unified standards for measurement, calibration, and data analysis makes it difficult to compare and aggregate multi-center data. This, in turn, has delayed the accumulation of large-scale clinical evidence and affected the general recognition of the technology's value.

Secondly,The Contradiction Between High Costs and Payment Mechanisms. Although room-temperature sensors have eliminated the need for liquid helium, high-end systems remain prohibitively expensive. Until clear reimbursement pathways and robust “cost-effectiveness” evidence are established, hospitals’ willingness to engage in large-scale procurement will inevitably be constrained.

The deeper challenge lies inIntegration of Clinical Pathways and Cultivation of Market Awareness. New technologies need to be integrated into existing diagnostic and treatment workflows, changing physicians' work habits, and demonstrating their systemic value in improving patient outcomes and reducing overall healthcare costs, which requires time, deep medical-engineering collaboration, and market education.

These challenges collectively point to a core issue: the “last mile” from technological breakthroughs to widespread clinical adoption. Just as MRI revolutionized medical imaging in the 1990s, zero-field magnetism medicine is fostering a paradigm shift in next-generation medical tools. The true competition lies not in larger models, lower noise, or stronger quantum capabilities, but in who can first transform this physics revolution into a “new normal” truly applicable to hundreds of real-world clinical scenarios.